Latest news and articles about Regeneron from NEX English
Regeneron Pharmaceuticals announced a historic agreement with U.S. President Donald Trump to reduce prices on certain medications in the United States. The deal also includes providing a new hearing loss treatment free of charge to eligible patients, reflecting ongoing efforts by the U.S. government to lower drug costs.
The U.S. Food and Drug Administration has approved the first gene therapy for treating genetic hearing loss, marking a significant advancement in genetic medicine. This decision follows years of research and clinical trials demonstrating the effectiveness of the new treatment.
U.S. President Donald Trump has announced a new agreement with Regeneron aimed at significantly reducing drug prices in the United States. This announcement comes at a critical time as citizens struggle with rising healthcare costs.